Listen: Verily’s moment of truth, Aduhelm’s rocky rollout, & the problem with Covid testing

Are we ever getting that Tricorder? Why’s it so hard to find Covid-19 tests? And is misinformation stopping Biogen from making money?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, STAT’s Erin Brodwin joins us to talk about Verily, Google’s big-idea life sciences company that is now under pressure to produce some actual products. Then, health care investor Bijan Salehizadeh calls in to discuss the dearth of rapid Covid-19 tests in the U.S. and how industry, regulators, and lawmakers share the blame. We also take a look at the latest news in biotech, including Biogen’s troubled launch of Aduhelm, Moderna’s long-term scientific ambitions, and a big day for the Waksal brothers.

For more on what we cover, here’s the Verily story; here’s Salehizadeh’s Twitter thread; here’s the latest from Biogen; here’s more on Kadmon Pharmaceuticals; here’s where you can subscribe to the First Opinion Podcast; and here’s our complete coverage of the Covid-19 pandemic.

Be sure to sign up on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Interested in sponsoring a future episode of “The Readout LOUD”? Email us at [email protected].